The loss of DDX3 in advanced cancer promotes CRC progression by activating the mitogen-activated protein kinase (MAPK) pathway, and targeting the MAPK pathway may be a therapeutic approach for advanced CRC. This evidence concerns the gene DDX3X and colorectal carcinoma.